

Docket No. 232234US0X/



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Brigitte BATHE, et al.

SERIAL NO: 10/630,740

GAU: 1615

FILED: July 31, 2003

EXAMINER:

FOR: PROCESS FOR THE PRODUCTION OF L-LYSINE USING CORYNEFORM BACTERIA

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

**REFERENCES**

- ☒ The applicant(s) wish to make of record the references cited in the attached International Search Report listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**RELATED CASES**

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

**CERTIFICATION**

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

**DEPOSIT ACCOUNT**

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.


  
Jean-Paul Lavalleye

Registration No. 31,451

Customer Number

**22850**

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Form PTO 1449  
(Modified)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

232234US0X

SERIAL NO.

10/630,740

## LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Brigitte BATHE, et al.

FILING DATE

July 31, 2003

GROUP

1615

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	3,871,960	03/18/1975	K. KUBOTA, et al.			
	AB	5,268,293	12/07/1993	J. W. OH, et al.			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	0 510 319	10/28/1992	GERMANY		X
	AP					
	AQ					
	AR					
	AS					
	AT					
	AU					
	AV					

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AW	D. H. SIMMONDS, Biochemical Journal, vol. 58, XP-008025012, pages 520-523, "ANALOGUES OF DIAMINOPIMELIC ACID AS INHIBITORS OF BACTERIAL GROWTH", 1954				
	AX	J. F. CAPLAN, et al., Organic Letters, vol. 2, no. 24, XP-002247986, pages 3857-3860, "VINYLOGOUS AMIDE ANALOGUES OF DIAMINOPIMELIC ACID (DAP) AS INHIBITORS OF ENZYMES INVOLVED IN BACTERIAL LYSINE BIOSYNTHESIS", November 10, 2000				
	AY	J.-M. GIRODEAU, et al., Journal of Medicinal Chemistry, vol. 29, no. 6, XP-000941834, pages 1023-1030, "THE LYSINE PATHWAY AS A TARGET FOR A NEW GENERA OF SYNTHETIC ANTIBACTERIAL ANTIBIOTICS?", 1986				
	AZ				<input type="checkbox"/> Additional References sheet(s) attached	

Examiner

Date Considered

\*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.